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variables. RESULTS: Expenditures on medicines declined due to
negative impact of EML on quantities of medicines utilized per
capita as well as on real prices. The quantities declined on
average by 1.7 DDDs per capita per year. The medicine price
reduced on average by about US $0.0013 per deﬁned daily dose.
The real cost saved for the years 2000 to 2003 was about US $
5.9 million. The EML was effective in shifting all prescribing
indicators towards the standard values. CONCLUSIONS: The
PMOH should allocate more resources for pharmaceutical
budget in the future. The EML was successful in containing med-
icine cost, and careful review and update of EML should further
increase the savings. The development and implementation of
antibiotic medicine policy is an urgent need. Introduction of
treatment protocols for the most common diseases, and con-
tinuous education on rational medicine use for medical staff 
is required.
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OBJECTIVE: Mandatory generic substitution of prescribed
drugs aiming to moderate the cost increase of pharmaceuticals
within the pharmaceutical beneﬁts scheme, PBS, was introduced
in October 2002. The study aims to investigate if the introduc-
tion of generic substitution had an impact on the development
of drugs costs in Sweden for prescribed drugs within PBS and in
total. METHODS: Data on the sales of pharmaceuticals to each
county council and to the country in total was obtained. Data
comprised both total sales (prescriptions, hospitals sales and over
the counter sales) and sales of prescribed drugs within the PBS
was used for the period January 2000 to May 2005. Expendi-
ture data was expressed as retail prices excluding VAT per 1000
inhabitants in Swedish krona (SEK). Interrupted time series
analysis was used to investigate effects related to generic substi-
tution. RESULTS: The county councils’ total cost for pharma-
ceuticals increased from 230 SEK/inhabitants in January 2000 to
280 SEK/inhabitant in May 2005. The county councils’ average
monthly costs for PBS pharmaceuticals lay in three segments one
had a constant cost of ~40 SEK/inhabitant over the study period,
the second segment increased from ~140 SEK/inhabitant in 2000
to ~170 SEK/inhabitant in late 2002 where it stabilized and the
third segment ~190 SEK/inhabitant in 2000 and increased to
~210 SEK/inhabitants in late 2002 and after that it was constant.
Generic substitution was associated with reduced the slope of
increase of costs for drugs within the PBS for the whole country
and several of the county councils according to preliminary
analyses. This was also seen for several of the county councils’
total costs immediately after the introduction of generic substi-
tution. CONCLUSIONS: Preliminary analyses show that generic
substitution had an impact in the pace of increase of pharma-
ceutical expenditures.
PHP18
GEOGRAPHICAL INFORMATION SYSTEM (GIS) ANALYSIS OF
SMALL AREA INEQUALITIES IN DRUG EXPENDITURES IN
HUNGARY
Boncz I1, David T1,Takacs E1, Sebestyen A2
1National Health Insurance Fund Administration (OEP), Budapest,
Hungary; 2National Health Insurance Fund Administration (OEP),
Pécs, Hungary
OBJECTIVES: The aim of this study is to analyse the small are
inequalities in the health insurance reimbursement of drugs in
Hungary. METHODS: Data derives from the central database
of the Hungarian National Health Insurance Fund Administra-
tion (OEP) covering the year 2003 and containing all the drug
reimbursement information from the whole country. For the
analysis we used three different kinds of drug expenditures
according to the source of funding: health insurance reimburse-
ment (paid by OEP), maximum reimbursement for socially hand-
icapped (coming from state budget), co-payment of patients
(paid out-of-pocket of patients) for subsidized drugs. The statis-
tical analysis was carried out with SPSS version 12.01. Small
areas refer to the postal code (zip code) districts of Hungary and
the patients were assigned to small areas according to their 
permanent address. The Geographical Information system (GIS)
analysis was carried out by the MapInfo Professional software
version 7.5. RESULTS: The health insurance reimbursement of
drugs paid by the National Health Insurance Fund Administra-
tion is signiﬁcantly higher (p < 0.05) in the southern and eastern
part of Hungary. The maximum reimbursement for socially
handicapped paid by the National Health Insurance Fund
Administration is also signiﬁcantly higher (p < 0.05) in the
eastern part of Hungary. The co-payment of patients is signiﬁ-
cantly higher (p < 0.05) in the western and central regions of
Hungary. The results are presented on GIS maps also. CON-
CLUSIONS: The GIS analyses help to identify the geographical
inequalities of the drug expenditures coming from different
sources. In the more developed regions (western and central
regions) the willingness and ability to pay the co-payment is
higher. In the less developed regions of Hungary (northern and
eastern regions) the people more rely on the reimbursement for
socially handicapped ﬁnanced from the state budget.
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OBJECTIVE: To investigate whether patients with a $1,000
annual prescription drug beneﬁt cap reduced their drug con-
sumption prior to exceeding the cap threshold. Previously, we
found that the drug cap reduced overall drug consumption
during the year. METHODS: All 183,640 subjects were 65+
years with Medicare insurance, had tiered copayments ($10 for
generic & $15–35 for brand drugs), and were members of an
integrated, prepaid delivery system: 146,050 subjects had an
annual $1000 drug beneﬁt limit; and 37,590 subjects had no
beneﬁt limit (because of supplementary insurance from former
employers rather than individual choice). To compare drug con-
sumption (measured in dollars) below the cap amount, we exam-
ined the risk of cap and non-cap subjects consuming $250, $500,
$750, and $1000 in 2003 using proportional hazard models for
each of these thresholds. We adjusted for age, gender, race/eth-
nicity, brand copayment amount, prior visits, socioeconomic
status, comorbidity, and having a regular primary care provider.
RESULTS: Among the 183,640 subjects, 16,657 (11%) of sub-
jects with a cap and 7,888 (21%) of subjects without caps
exceeded the $1,000 cap threshold during 2003. After adjust-
ment for covariates, subjects with a cap were signiﬁcantly less
likely to exceed the $1,000 cap threshold (HR = 0.61, 95% CI:
0.56–0.66), compared with subjects without a cap. Similarly,
subjects with a cap were signiﬁcantly less likely to exceed lower
drug consumption thresholds during the year, compared with
